home / stock / stsa / stsa news

STSA News and Press, Satsuma Pharmaceuticals Inc. From 08/02/22

Stock Information
Company Name: Satsuma Pharmaceuticals Inc.
Stock Symbol: STSA
Market: NYSE
Menu
STSA STSA Quote STSA Short STSA News STSA Articles STSA Message Board
Get STSA Alerts

News, Short Squeeze, Breakout and More Instantly...
STSA - Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

- More than 1,400 subjects randomized - - Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company deve...
STSA - Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

STSA - Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

STSA - Yumanity, Babylon top healthcare gainers; while Praxis, eFFECTOR lead losers' pack

Gainers:  Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
STSA - Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment...

STSA - Satsuma Pharmaceuticals GAAP EPS of -$0.49 in-line

Satsuma Pharmaceuticals press release (NASDAQ:STSA): Q1 GAAP EPS of -$0.49 in-line. $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second half of 2023 For further details see: Satsuma Pharmaceuticals GAAP EPS of -$0.49 in-lin...

STSA - Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 - - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, prov...
STSA - Satsuma Pharmaceuticals GAAP EPS of -$0.49

Satsuma Pharmaceuticals press release (NASDAQ:STSA): Q4 GAAP EPS of -$0.49. As of December 31, 2021, Satsuma had $95.8 million in combined cash, cash equivalents and marketable securities. For further details see: Satsuma Pharmaceuticals GAAP EPS of -$0.49

STSA - Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 - SOUTH SAN FRANCISC...

STSA - Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...
Previous 10 Next 10